It has been reported that Dkk3 might orchestrate concomitant activation of β-catenin and YAP/TAZ in cancer-associated fibroblasts (CAFs) by interfering with the Kremen negative regulator and increasing cell-surface levels of LRP6 as an HSF1 effector, required to promote tumor aggressiveness (41). The gene discussed is LRP6; the disease is cancer.